Fresh Tracks Therapeutics... (FRTX)
NASDAQ: FRTX
· Real-Time Price · USD
0.94
0.00 (0.00%)
At close: Feb 28, 2025, 12:19 PM
Fresh Tracks Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 8.01M | 10.06M | 2.6M | 6.86M | 6.94M | 5M | 4.64M | 479K | 404K | 327K | 337K | 793K |
Cost of Revenue | 2.54M | 5.15M | 8.71M | 9.97M | 14.04M | 14.56M | 21.22M | 28.19M | 28.23M | 29.67M | 20.73M | 14.6M |
Gross Profit | 5.46M | 4.91M | -6.11M | -3.11M | -7.1M | -9.56M | -16.58M | -27.71M | -27.83M | -29.34M | -20.39M | -13.81M |
Operating Income | -6.36M | -9.3M | -17.37M | -16.47M | -21.53M | -23.25M | -30.53M | -40.65M | -40.24M | -41.34M | -32.33M | -25.88M |
Interest Income | 5K | 5K | 5K | 3K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -5.89M | -9.18M | -17.11M | -15.97M | -21.1M | -22.64M | -29.88M | -39.88M | -39.47M | -40.77M | -31.84M | -25.82M |
Net Income | -5.63M | -8.92M | -16.98M | -15.54M | -20.74M | -22.28M | -29.57M | -39.88M | -39.47M | -40.77M | -31.84M | -25.82M |
Selling & General & Admin | 11.18M | 13.58M | 11.26M | 13.36M | 14.43M | 13.69M | 13.95M | 12.94M | 12.42M | 12M | 11.94M | 12.07M |
Research & Development | 3.18M | 5.78M | 8.71M | 9.97M | 14.04M | 14.56M | 21.22M | 28.19M | 28.23M | 29.67M | 20.73M | 14.6M |
Other Expenses | 150K | 150K | 208K | 439K | 372K | 372K | 421K | 567K | 597K | 597K | 490K | 31K |
Operating Expenses | 14.37M | 19.36M | 19.97M | 23.33M | 28.48M | 28.24M | 35.17M | 41.13M | 40.65M | 41.67M | 32.67M | 26.67M |
Interest Expense | 5K | 8K | 8K | 8K | 9K | 10K | 11K | 39K | 69K | 65K | 64K | 34K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 14.37M | 19.36M | 19.97M | 23.33M | 28.48M | 28.24M | 35.17M | 41.13M | 40.65M | 41.67M | 32.67M | 26.67M |
Income Tax Expense | -73K | -73K | -120K | -431K | -366K | -362K | -303K | 38K | 69K | 64K | 63K | 33K |
Shares Outstanding (Basic) | 5.91M | 5.91M | 5.91M | 3.76M | 3.01M | 2.91M | 2.66M | 2.65M | 2.4M | 1.85M | 1.53M | 1.36M |
Shares Outstanding (Diluted) | 5.91M | 5.91M | 5.91M | 3.76M | 3.01M | 2.91M | 2.66M | 2.65M | 2.4M | 1.85M | 1.53M | 1.36M |
EPS (Basic) | -1.4 | -2.69 | -5.06 | -4.98 | -7.41 | -8.44 | -13.54 | -20.52 | -23.6 | -27.91 | -27.69 | -39.89 |
EPS (Diluted) | -1.4 | -2.69 | -5.06 | -4.98 | -7.41 | -8.44 | -13.54 | -20.52 | -23.6 | -27.91 | -27.69 | -39.89 |
EBITDA | -5.77M | -9.05M | -17.06M | -15.93M | -21.06M | -22.6M | -29.84M | -39.81M | -39.38M | -40.69M | -31.77M | -25.77M |
EBIT | -5.69M | -8.97M | -17.1M | -15.96M | -21.09M | -22.63M | -29.87M | -39.84M | -39.41M | -40.71M | -31.78M | -25.78M |
Depreciation & Amortization | 41K | 40K | 37K | 33K | 30K | 28K | 27K | 28K | 22K | 16K | 12K | 8K |